<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02007720</url>
  </required_header>
  <id_info>
    <org_study_id>CRLX030A2302</org_study_id>
    <nct_id>NCT02007720</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF</brief_title>
  <acronym>RELAX-AHF-ASIA</acronym>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo Controlled Phase III Study to Evaluate the Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in Acute Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study was to evaluate the efficacy, safety and tolerability of intravenous
      infusion of serelaxin, when added to standard therapy, in acute heart failure (AHF) patients.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study was terminated based on results from pivotal adult AHF study CRLX030A2301
  </why_stopped>
  <start_date type="Actual">March 12, 2014</start_date>
  <completion_date type="Actual">June 16, 2017</completion_date>
  <primary_completion_date type="Actual">March 27, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With a Clinical Composite Endpoint of Treatment Success, Treatment Failure, or no Change.</measure>
    <time_frame>through day 5</time_frame>
    <description>The trichotomous clinical composite endpoint of treatment success, treatment failure, or no change. Treatment success defined as improvement of dyspnea by Likert scale and at least 2 points improvement by at least 2 physician assessed signs and symptoms (orthopnea, rales edema, and jugular venous pulse) at Day 2; treatment failure defined as worsening heart failure, death, or re-hospitalization due to heart failure or renal failure through Day 5; no change defined as neither the criteria for treatment success nor the criteria for treatment failure was met through Day 5.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to WHF</measure>
    <time_frame>Through Day 5</time_frame>
    <description>Results are given in terms of number of participants with at least one worsening heart failure (WHF) event through day 5 (pre-defined timeframe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CV Death</measure>
    <time_frame>Through Day 180</time_frame>
    <description>analysis of time to CEC CV death through day 180 : results are given in terms of number of participants with CV death event through day 180 (pre-defined timeframe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to All-cause Death</measure>
    <time_frame>Through Day 180</time_frame>
    <description>Results are given in terms of number of participants with all cause death event through day 180 (pre-defined timeframe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Moderate or Marked Improvements in Dyspnea by Likert Scale, Expressed in Days</measure>
    <time_frame>Through Day 5</time_frame>
    <description>Time to event is computed as the number of days from randomization to moderate or marked improvements in dyspnea by Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea by VAS-AUC Changes</measure>
    <time_frame>Through Day 5</time_frame>
    <description>Change from baseline in Dyspena by VAS-AUC through Day 5, expressed in mm-hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of Intensive Care Unit (ICU) and/or Coronary Care Unit (CCU) Stay for the Index AHF Hospitalization</measure>
    <time_frame>Up to day 30</time_frame>
    <description>Length of stay will be defined as the hospitalization discharge date and the time minus the baseline date and time plus 1 day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal Dysfunction and Prevention of Worsening of Renal Function</measure>
    <time_frame>Through Day 5</time_frame>
    <description>number of participants with renal dysfunction or in-hospital worsening of renal function through Day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Re-hospitalization Due to Heart Failure and Renal Impairment</measure>
    <time_frame>Through Day 180</time_frame>
    <description>Time to event is computed as the number of days from randomization to re-hospitalization due to Heart Failure and renal impairment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to CV Death or Re-hospitalization Due to Heart Failure/ Renal Failure</measure>
    <time_frame>Through Day 180</time_frame>
    <description>Results are given in terms of number of participants with CV death or at least one re-hospitalization due to Heart Failure through day 180 (pre-defined timeframe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to In-hospital Worsening Heart Failure Through Day 5</measure>
    <time_frame>Through Day 5</time_frame>
    <description>Results are given in terms of number of participants with at least one in-hospital worsening heart failure through day 5 (pre-defined timeframe). In-hospital worsening heart failure is defined by symptoms only, signs only, and both symptoms and signs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Loop Diuretic and Vasoactive Agents</measure>
    <time_frame>Through Day 5</time_frame>
    <description>Number of patients reported with use of loop diuretic and vasoactive agents from randomization through Day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cardio-renal Biomarkers</measure>
    <time_frame>Day 2 and Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Reported With Total Adverse Events, Serious Adverse Events and Death.</measure>
    <time_frame>For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.</time_frame>
    <description>To evaluate the safety and tolerability of intravenous serelaxin in AHF patients, number of patients with total adverse events, serious adverse events and death will be analyzed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">876</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Serelaxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive continuous intravenous infusion of serelaxin(30 µg/kg/day) for 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Serelaxin</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Serelaxin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of CareTherapy</intervention_name>
    <description>This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>Serelaxin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥ 18 years of age, with body weight ≤160 kg

          -  Hospitalized for AHF; AHF is defined as including all of the following measured at any
             time between presentation (including the emergency department and outpatient clinic)
             and at the end of screening:

               -  Persistent dyspnea at rest or with minimal exertion at screening and at the time
                  of randomization

               -  Pulmonary congestion on chest radiograph

               -  Brain natriuretic peptide (BNP) ≥500 pg/mL or NT-proBNP ≥2,000 pg/mL

          -  Systolic BP ≥125 mmHg at the start and at the end of screening

          -  Able to be randomized within 16 hours from presentation to the hospital, including the
             emergency department and outpatient clinic

          -  Received intravenous furosemide of at least 40 mg total (or equivalent) at any time
             between presentation (this includes outpatient clinic, ambulance, or hospital
             including emergency department) and the start of screening for the study for the
             treatment of the current acute HF episode

          -  Renal impairment defined as an estimate glomerular filtration rate using the between
             presentation and randomization of ≥ 25 and ≤75mL/min/1.73m2, calculated using the
             Modification of Diet in Renal Disease formula (or modified sMDRD formula according to
             specific ethnic groups and local practice guidelines).

        Exclusion Criteria:

          -  Dyspnea primarily due to non-cardiac causes

          -  Temperature &gt;38.5°C (oral or equivalent), sepsis, active and clinically significant
             infection requiring IV anti-microbial treatment or known presence or evidence of Human
             Immunodeficiency Virus (HIV) infection (based on history and/or clinical findings,
             including laboratory results obtained during screening period).

          -  Clinical evidence of acute coronary syndrome currently or within 30 days prior to
             enrollment

             *Patients with systolic blood pressure &gt;180 mmHg at the end of screening

          -  AHF due to significant arrhythmias, which include any of the following: sustained
             ventricular tachycardia, bradycardia with sustained ventricular rate &lt;45 beats per
             minute, or atrial fibrillation/flutter with sustained ventricular response of &gt;130
             beats per minute

          -  Hepatic disease unrelated to Heart Failure etiology and as determined by any one of
             the following: AST and/or ALT values exceeding 3 X ULN and/or bilirubin &gt; 1.5 X ULN at
             screening or history of hepatic encephalopathy, esophageal varices, or portacaval
             shunt, or a diagnosis of cirrhosis by any means, or evidence of chronic Hepatitis B
             (presence of hepatitis B surface antigen production: positive HBsAg), or chronic
             Hepatitis C infection (presence of Hepatitis C genetic replication: positive Hepatitis
             C viral RNA, based on history and/or clinical findings, including laboratory results
             obtained during screening period).

             *Significant uncorrected left ventricular outflow obstruction, such as obstructive
             hypertrophic cardiomyopathy or severe aortic stenosis (i.e., aortic valve area &lt;1.0
             cm2 or mean gradient &gt;50 mmHg on prior or current echocardiogram), and severe mitral
             stenosis

          -  History of malignancy of any organ system (other than localized basal cell carcinoma
             of the skin), treated or untreated, within the past year with a life expectancy less
             than 1 year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>51000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jinshan</city>
        <state>Shanghai</state>
        <zip>201508</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Xian</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300121</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wenzhou</city>
        <state>Zhejiang</state>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beijing</city>
        <zip>100050</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chongqing</city>
        <zip>400037</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shanghai City</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110029</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ahmedabad</city>
        <state>Gujarat</state>
        <zip>380054</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vadodara</city>
        <state>Gujarat</state>
        <zip>390022</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440010</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagpur</city>
        <state>Maharashtra</state>
        <zip>440012</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600101</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hyderabad</city>
        <state>Telangana</state>
        <zip>500082</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rajasthan</city>
        <zip>334003</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagakute-city</city>
        <state>Aichi</state>
        <zip>480-1195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seto-city</city>
        <state>Aichi</state>
        <zip>489-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kamogawa-city</city>
        <state>Chiba</state>
        <zip>2968602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saijo-city</city>
        <state>Ehime</state>
        <zip>793-0027</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chikushino-city</city>
        <state>Fukuka</state>
        <zip>818-8516</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>810-0001</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>811-0213</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>815-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Iizuka-city</city>
        <state>Fukuoka</state>
        <zip>820-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kurume-city</city>
        <state>Fukuoka</state>
        <zip>830-8543</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kurume-city</city>
        <state>Fukuoka</state>
        <zip>830-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ogaki-city</city>
        <state>Gifu</state>
        <zip>503-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kushiro-city</city>
        <state>Hokkaido</state>
        <zip>085-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>006-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amagasaki city</city>
        <state>Hyogo</state>
        <zip>660 8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe-City</city>
        <state>Hyogo</state>
        <zip>654-0155</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mito-city</city>
        <state>Ibaraki</state>
        <zip>311-4198</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kanazawa</city>
        <state>Ishikawa</state>
        <zip>920 8650</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kanonji-city</city>
        <state>Kagawa</state>
        <zip>769-1695</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Takamatsu city</city>
        <state>Kagawa</state>
        <zip>760 8557</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki-city</city>
        <state>Kanagawa</state>
        <zip>211-8533</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama city</city>
        <state>Kanagawa</state>
        <zip>232 0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>227-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>231-8682</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yokohama-city</city>
        <state>Kanagawa</state>
        <zip>236 0051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kochi city</city>
        <state>Kochi</state>
        <zip>781 8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kumamoto-city</city>
        <state>Kumamoto</state>
        <zip>861-4193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yatsushiro-city</city>
        <state>Kumamoto</state>
        <zip>866-8660</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto-city</city>
        <state>Kyoto</state>
        <zip>607-8062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Uji-city</city>
        <state>Kyoto</state>
        <zip>611-0042</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai-city</city>
        <state>Miyagi</state>
        <zip>981-3133</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nakano-city</city>
        <state>Nagano</state>
        <zip>383-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saku-city</city>
        <state>Nagano</state>
        <zip>3850051</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ueda-city</city>
        <state>Nagano</state>
        <zip>386-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niigata-city</city>
        <state>Niigata</state>
        <zip>950-1197</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka-city</city>
        <state>Osaka</state>
        <zip>540-0006</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawaguchi-city</city>
        <state>Saitama</state>
        <zip>333-0842</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sayama-city</city>
        <state>Saitama</state>
        <zip>350-1323</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wako-city</city>
        <state>Saitama</state>
        <zip>351-0102</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kusatsu city</city>
        <state>Shiga</state>
        <zip>525 8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamamatsu-city</city>
        <state>Shizuoka</state>
        <zip>430-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kakegawa-city</city>
        <state>Shizuoka</state>
        <zip>436-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Akishima-city</city>
        <state>Tokyo</state>
        <zip>196-0003</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo ku</city>
        <state>Tokyo</state>
        <zip>104-8560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hachioji-city</city>
        <state>Tokyo</state>
        <zip>192-0918</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>173-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Musashino-city</city>
        <state>Tokyo</state>
        <zip>180-8610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa ku</city>
        <state>Tokyo</state>
        <zip>141 8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>142-8666</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tanabe-city</city>
        <state>Wakayama</state>
        <zip>646-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>534-0021</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saitama</city>
        <zip>330 8503</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amman</city>
        <state>JOR</state>
        <zip>11152</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amman</city>
        <zip>11183</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Amman</city>
        <zip>11184</zip>
        <country>Jordan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gyeonggi do</city>
        <state>Bucheon Si</state>
        <zip>422-711</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cheongju si</city>
        <state>Chungcheongbuk Do</state>
        <zip>28644</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon-do</state>
        <zip>26427</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bundang Gu</city>
        <state>Gyeonggi Do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Korea</state>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <state>Seocho Gu</state>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Busan</city>
        <zip>602739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Incheon</city>
        <zip>405 760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ashrafieh</city>
        <zip>166830</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beirut</city>
        <zip>1107 2020</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Beirut</city>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hazmieh</city>
        <zip>470</zip>
        <country>Lebanon</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>MYS</state>
        <zip>56000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kota Kinabalu</city>
        <state>Sabah</state>
        <zip>88300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>94300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <state>Selangor Darul Ehsan</state>
        <zip>43000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sungai Buloh</city>
        <state>Selangor Darul Ehsan</state>
        <zip>47000</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <state>Manila</state>
        <zip>1100</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manila</city>
        <state>Metro Manila</state>
        <zip>1000</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Makati City</city>
        <zip>1229</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Manila</city>
        <zip>1003</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pasig City</city>
        <zip>1605</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1102</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Quezon City</city>
        <zip>1113</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Juan City</city>
        <zip>1500</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>117549</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169609</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Changhua</city>
        <zip>50006</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung City</city>
        <zip>83301</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaohsiung</city>
        <zip>80756</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Taipei</city>
        <zip>22060</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>11217</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taoyuan</city>
        <zip>33305</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Yilan</city>
        <zip>26058</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Songkhla</city>
        <state>Hat Yai</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Muang</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
    <country>India</country>
    <country>Japan</country>
    <country>Jordan</country>
    <country>Korea, Republic of</country>
    <country>Lebanon</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Taiwan</country>
    <country>Thailand</country>
  </location_countries>
  <removed_countries>
    <country>Hong Kong</country>
  </removed_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>November 20, 2013</study_first_submitted>
  <study_first_submitted_qc>December 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2013</study_first_posted>
  <results_first_submitted>May 14, 2018</results_first_submitted>
  <results_first_submitted_qc>June 12, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 2, 2019</results_first_posted>
  <last_update_submitted>June 12, 2019</last_update_submitted>
  <last_update_submitted_qc>June 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Serelaxin,</keyword>
  <keyword>WHF,</keyword>
  <keyword>Likert Scale,</keyword>
  <keyword>RELAX-AHF-ASIA,</keyword>
  <keyword>RLX030,</keyword>
  <keyword>AHF,</keyword>
  <keyword>acute heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 10, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02007720/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 23, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/20/NCT02007720/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>patient randomized : participants who signed ICF (876 participants)
Full analyis set: participants who received at least one dose of study drug (870 participants)
safety set (858 participtants): participants who received at least one dose of study drug and completed at least one post baseline assessment</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
        </group>
        <group group_id="P2">
          <title>Serelaxin</title>
          <description>Patients who receivedcontinuous intravenous infusion of serelaxin for 48 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="436"/>
                <participants group_id="P2" count="440"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="433"/>
                <participants group_id="P2" count="437"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Set</title>
              <participants_list>
                <participants group_id="P1" count="426"/>
                <participants group_id="P2" count="432"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="354"/>
                <participants group_id="P2" count="368"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="82"/>
                <participants group_id="P2" count="72"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="54"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>technical problem</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>patient followd less than 165 days</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set was used</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
        </group>
        <group group_id="B2">
          <title>Serelaxin</title>
          <description>Patients who receivedcontinuous intravenous infusion of serelaxin for 48 hours.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="433"/>
            <count group_id="B2" value="437"/>
            <count group_id="B3" value="870"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>full analysis set 870 participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.2" spread="13.86"/>
                    <measurement group_id="B2" value="68.9" spread="14.40"/>
                    <measurement group_id="B3" value="69.6" spread="14.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="165"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="312"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="268"/>
                    <measurement group_id="B2" value="290"/>
                    <measurement group_id="B3" value="558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="418"/>
                    <measurement group_id="B2" value="420"/>
                    <measurement group_id="B3" value="838"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With a Clinical Composite Endpoint of Treatment Success, Treatment Failure, or no Change.</title>
        <description>The trichotomous clinical composite endpoint of treatment success, treatment failure, or no change. Treatment success defined as improvement of dyspnea by Likert scale and at least 2 points improvement by at least 2 physician assessed signs and symptoms (orthopnea, rales edema, and jugular venous pulse) at Day 2; treatment failure defined as worsening heart failure, death, or re-hospitalization due to heart failure or renal failure through Day 5; no change defined as neither the criteria for treatment success nor the criteria for treatment failure was met through Day 5.</description>
        <time_frame>through day 5</time_frame>
        <population>Full analysis set (FAS) - All patients in the randomized population who were not misrandomized patients. Following the intent-to-treat (ITT) principle, patients were analyzed according to the treatment they had been assigned to at the randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin</title>
            <description>Patients who receivedcontinuous intravenous infusion of serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With a Clinical Composite Endpoint of Treatment Success, Treatment Failure, or no Change.</title>
          <description>The trichotomous clinical composite endpoint of treatment success, treatment failure, or no change. Treatment success defined as improvement of dyspnea by Likert scale and at least 2 points improvement by at least 2 physician assessed signs and symptoms (orthopnea, rales edema, and jugular venous pulse) at Day 2; treatment failure defined as worsening heart failure, death, or re-hospitalization due to heart failure or renal failure through Day 5; no change defined as neither the criteria for treatment success nor the criteria for treatment failure was met through Day 5.</description>
          <population>Full analysis set (FAS) - All patients in the randomized population who were not misrandomized patients. Following the intent-to-treat (ITT) principle, patients were analyzed according to the treatment they had been assigned to at the randomization</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="314"/>
                    <measurement group_id="O2" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                    <measurement group_id="O2" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to WHF</title>
        <description>Results are given in terms of number of participants with at least one worsening heart failure (WHF) event through day 5 (pre-defined timeframe).</description>
        <time_frame>Through Day 5</time_frame>
        <population>Full analysis set (FAS) - All patients in the randomized population who were not misrandomized patients*. Following the intent-to-treat (ITT) principle, patients were analyzed according to the treatment they had been assigned to at the randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin</title>
            <description>Patients who receivedcontinuous intravenous infusion of serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to WHF</title>
          <description>Results are given in terms of number of participants with at least one worsening heart failure (WHF) event through day 5 (pre-defined timeframe).</description>
          <population>Full analysis set (FAS) - All patients in the randomized population who were not misrandomized patients*. Following the intent-to-treat (ITT) principle, patients were analyzed according to the treatment they had been assigned to at the randomization</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to CV Death</title>
        <description>analysis of time to CEC CV death through day 180 : results are given in terms of number of participants with CV death event through day 180 (pre-defined timeframe).</description>
        <time_frame>Through Day 180</time_frame>
        <population>Full analysis set (FAS) - All patients in the randomized population who were not misrandomized patients*. Following the intent-to-treat (ITT) principle, patients were analyzed according to the treatment they had been assigned to at the randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin</title>
            <description>Patients who receivedcontinuous intravenous infusion of serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to CV Death</title>
          <description>analysis of time to CEC CV death through day 180 : results are given in terms of number of participants with CV death event through day 180 (pre-defined timeframe).</description>
          <population>Full analysis set (FAS) - All patients in the randomized population who were not misrandomized patients*. Following the intent-to-treat (ITT) principle, patients were analyzed according to the treatment they had been assigned to at the randomization</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to All-cause Death</title>
        <description>Results are given in terms of number of participants with all cause death event through day 180 (pre-defined timeframe).</description>
        <time_frame>Through Day 180</time_frame>
        <population>Full analysis set (FAS) - All patients in the randomized population who were not misrandomized patients*. Following the intent-to-treat (ITT) principle, patients were analyzed according to the treatment they had been assigned to at the randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin</title>
            <description>Patients who receivedcontinuous intravenous infusion of serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to All-cause Death</title>
          <description>Results are given in terms of number of participants with all cause death event through day 180 (pre-defined timeframe).</description>
          <population>Full analysis set (FAS) - All patients in the randomized population who were not misrandomized patients*. Following the intent-to-treat (ITT) principle, patients were analyzed according to the treatment they had been assigned to at the randomization</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Moderate or Marked Improvements in Dyspnea by Likert Scale, Expressed in Days</title>
        <description>Time to event is computed as the number of days from randomization to moderate or marked improvements in dyspnea by Likert scale</description>
        <time_frame>Through Day 5</time_frame>
        <population>Full analysis set (FAS)with measure</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin</title>
            <description>Patients who receivedcontinuous intravenous infusion of serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Moderate or Marked Improvements in Dyspnea by Likert Scale, Expressed in Days</title>
          <description>Time to event is computed as the number of days from randomization to moderate or marked improvements in dyspnea by Likert scale</description>
          <population>Full analysis set (FAS)with measure</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="423"/>
                <count group_id="O2" value="429"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.327" spread="1.4418"/>
                    <measurement group_id="O2" value="1.352" spread="1.5071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnea by VAS-AUC Changes</title>
        <description>Change from baseline in Dyspena by VAS-AUC through Day 5, expressed in mm-hours</description>
        <time_frame>Through Day 5</time_frame>
        <population>full analysis set with measure</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin</title>
            <description>Patients who receivedcontinuous intravenous infusion of serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Dyspnea by VAS-AUC Changes</title>
          <description>Change from baseline in Dyspena by VAS-AUC through Day 5, expressed in mm-hours</description>
          <population>full analysis set with measure</population>
          <units>mm-hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="429"/>
                <count group_id="O2" value="432"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2284.6" spread="2702.34"/>
                    <measurement group_id="O2" value="2358.2" spread="2321.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Length of Intensive Care Unit (ICU) and/or Coronary Care Unit (CCU) Stay for the Index AHF Hospitalization</title>
        <description>Length of stay will be defined as the hospitalization discharge date and the time minus the baseline date and time plus 1 day</description>
        <time_frame>Up to day 30</time_frame>
        <population>full analysis set with measure</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin</title>
            <description>Patients who receivedcontinuous intravenous infusion of serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Length of Intensive Care Unit (ICU) and/or Coronary Care Unit (CCU) Stay for the Index AHF Hospitalization</title>
          <description>Length of stay will be defined as the hospitalization discharge date and the time minus the baseline date and time plus 1 day</description>
          <population>full analysis set with measure</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="5.13"/>
                    <measurement group_id="O2" value="2.5" spread="4.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Renal Dysfunction and Prevention of Worsening of Renal Function</title>
        <description>number of participants with renal dysfunction or in-hospital worsening of renal function through Day 5</description>
        <time_frame>Through Day 5</time_frame>
        <population>Full analysis set with measure</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin</title>
            <description>Patients who receivedcontinuous intravenous infusion of serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Renal Dysfunction and Prevention of Worsening of Renal Function</title>
          <description>number of participants with renal dysfunction or in-hospital worsening of renal function through Day 5</description>
          <population>Full analysis set with measure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="418"/>
                <count group_id="O2" value="416"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="120"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Re-hospitalization Due to Heart Failure and Renal Impairment</title>
        <description>Time to event is computed as the number of days from randomization to re-hospitalization due to Heart Failure and renal impairment</description>
        <time_frame>Through Day 180</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin</title>
            <description>Patients who receivedcontinuous intravenous infusion of serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Re-hospitalization Due to Heart Failure and Renal Impairment</title>
          <description>Time to event is computed as the number of days from randomization to re-hospitalization due to Heart Failure and renal impairment</description>
          <units>days</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="82"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to CV Death or Re-hospitalization Due to Heart Failure/ Renal Failure</title>
        <description>Results are given in terms of number of participants with CV death or at least one re-hospitalization due to Heart Failure through day 180 (pre-defined timeframe).</description>
        <time_frame>Through Day 180</time_frame>
        <population>Full analysis set (FAS) - All patients in the randomized population who were not misrandomized patients*. Following the intent-to-treat (ITT) principle, patients were analyzed according to the treatment they had been assigned to at the randomization</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin</title>
            <description>Patients who receivedcontinuous intravenous infusion of serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to CV Death or Re-hospitalization Due to Heart Failure/ Renal Failure</title>
          <description>Results are given in terms of number of participants with CV death or at least one re-hospitalization due to Heart Failure through day 180 (pre-defined timeframe).</description>
          <population>Full analysis set (FAS) - All patients in the randomized population who were not misrandomized patients*. Following the intent-to-treat (ITT) principle, patients were analyzed according to the treatment they had been assigned to at the randomization</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                    <measurement group_id="O2" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to In-hospital Worsening Heart Failure Through Day 5</title>
        <description>Results are given in terms of number of participants with at least one in-hospital worsening heart failure through day 5 (pre-defined timeframe). In-hospital worsening heart failure is defined by symptoms only, signs only, and both symptoms and signs.</description>
        <time_frame>Through Day 5</time_frame>
        <population>Full analysis set with measure</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin</title>
            <description>Patients who receivedcontinuous intravenous infusion of serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to In-hospital Worsening Heart Failure Through Day 5</title>
          <description>Results are given in terms of number of participants with at least one in-hospital worsening heart failure through day 5 (pre-defined timeframe). In-hospital worsening heart failure is defined by symptoms only, signs only, and both symptoms and signs.</description>
          <population>Full analysis set with measure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>WHF through day 5 by symptoms</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WHF through day 5 by signs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>WHF through day 5 by both</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>death through day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Loop Diuretic and Vasoactive Agents</title>
        <description>Number of patients reported with use of loop diuretic and vasoactive agents from randomization through Day 5</description>
        <time_frame>Through Day 5</time_frame>
        <population>full analysis set with measure</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin</title>
            <description>Patients who receivedcontinuous intravenous infusion of serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Loop Diuretic and Vasoactive Agents</title>
          <description>Number of patients reported with use of loop diuretic and vasoactive agents from randomization through Day 5</description>
          <population>full analysis set with measure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="432"/>
                <count group_id="O2" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cardio-renal Biomarkers</title>
        <time_frame>Day 2 and Day 5</time_frame>
        <population>The data was not collected, and analysis not performed, as the trial was terminated prematurely</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin</title>
            <description>Patients who receivedcontinuous intravenous infusion of serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cardio-renal Biomarkers</title>
          <population>The data was not collected, and analysis not performed, as the trial was terminated prematurely</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Reported With Total Adverse Events, Serious Adverse Events and Death.</title>
        <description>To evaluate the safety and tolerability of intravenous serelaxin in AHF patients, number of patients with total adverse events, serious adverse events and death will be analyzed.</description>
        <time_frame>For the safety evaluation, all adverse events will be collected from signing of the informed consent form through Day 5 for non-serious AEs and through Day 14 for serious AEs.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
          </group>
          <group group_id="O2">
            <title>Serelaxin</title>
            <description>Patients who receivedcontinuous intravenous infusion of serelaxin for 48 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Reported With Total Adverse Events, Serious Adverse Events and Death.</title>
          <description>To evaluate the safety and tolerability of intravenous serelaxin in AHF patients, number of patients with total adverse events, serious adverse events and death will be analyzed.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="433"/>
                <count group_id="O2" value="437"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>number of participants with SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of participants with AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253"/>
                    <measurement group_id="O2" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of patients with death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion, an average of 3 years</time_frame>
      <desc>AE additional description</desc>
      <group_list>
        <group group_id="E1">
          <title>RLX030</title>
          <description>RLX030</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Patients who received continuous intravenous infusion of matching placebo serelaxin for 48 hours.</description>
        </group>
        <group group_id="E3">
          <title>Total</title>
          <description>Total</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="75" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="50" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Splenic infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Cardiac failure acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vitreous haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Infusion site thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acinetobacter infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Medical device site infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Serratia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood pressure decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Embolic cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Hypercapnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (20.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="65" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="147" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="432"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="426"/>
                <counts group_id="E3" subjects_affected="74" subjects_at_risk="858"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However Novartis does not prohibit any inverstigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharma AG</organization>
      <phone>+41613241111</phone>
      <email>novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

